US Zulassung + Partnerschaft in 2010 = TOP PICK

Seite 1 von 2
neuester Beitrag: 27.07.17 17:21
eröffnet am: 11.03.10 18:59 von: Biotechmaste. Anzahl Beiträge: 41
neuester Beitrag: 27.07.17 17:21 von: centsucher Leser gesamt: 12088
davon Heute: 1
bewertet mit 4 Sternen

Seite: Zurück 1 | 2 Weiter  

205 Postings, 4766 Tage BiotechmasterUS Zulassung + Partnerschaft in 2010 = TOP PICK

11.03.10 18:59
Diese Aktie gehört wohl zu den günstigsten Biotechs überhaupt aber am besten macht eure Hausaufgaben selbst und ihr werdet staunen .

Hier hat man die Chance wirklich sehr gutes geld zu verdienen .

IntelliPharmaceutics (IPCI)

Marktkap: 17 Mio$
Cash: 8 Mio$
Kurs: 1,50 $

Shares Out: 10,9 M


Präsentation März 2010

Intellipharmaceutics' development milestones for 2010 include the following:

-- Potential conclusion of the ongoing litigation process and/or FDA
approval of Focalin XR

-- File and have accepted for review by the FDA, two additional ANDA applications

-- Establish at least one additional development/marketing alliance

-- Complete successful manufacturing of clinical batches of Rexista(TM)

-- Complete Phase 1 studies using clinical batches of Rexista(TM)

-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical
development plan  
Seite: Zurück 1 | 2 Weiter  
15 Postings ausgeblendet.

32 Postings, 2820 Tage retti1977Wann starten wir durch?

01.07.15 13:47
Can Intellipharmaceutics International Inc. (NASDAQ:IPCI) Keep Up with Analyst Expectations?

on June 30, 2015  

32 Postings, 2820 Tage retti1977Gute News!

09.07.15 13:28
Monster News!

the United States Food and Drug Administration ("FDA") has indicated to the Company that it has rescinded its previous requirement that the Company meet newly-imposed conditions for bioequivalence prior to receiving final approval for the Company?s tentatively-approved strengths of its generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules (the ?Product?). The strengths affected include 5 mg, 10 mg, 20 mg and 40 mg. The already-approved 15 mg and 30 mg strengths now in the market are not affected.


32 Postings, 2820 Tage retti1977wie weit geht heut die Reise?

09.07.15 15:27

32 Postings, 2820 Tage retti1977Wir steigen und steigen!

15.07.15 18:06
Bald die 4$ Marke!!!  

41053 Postings, 3307 Tage wallanderIPCI $2.26

12.01.16 16:04
interessant... +50% sollten drinn sein oder, m.M.  
Angehängte Grafik:
ipci.png (verkleinert auf 73%) vergrößern

41053 Postings, 3307 Tage wallanderauf Jahressicht :-)

12.01.16 16:07

41053 Postings, 3307 Tage wallanderTH $2.74

14.01.16 17:22

41053 Postings, 3307 Tage wallanderna sieh mal einer an, löppt ja :-)

25.02.16 22:25
prima... $$$  
Angehängte Grafik:
ipci2.png (verkleinert auf 72%) vergrößern

22393 Postings, 4678 Tage Balu4uGeht was?

26.04.16 09:47

728 Postings, 3126 Tage Poldi278Anda's

08.06.16 12:28
Bis wann sollen eigentlich diese Anträge von 2010/11 genehmigt werden?In 2020 oder was?Verstehen muss man das nicht oder?  

150 Postings, 3852 Tage RainbowfuTut sich schwer

17.10.16 22:25
spricht prinzipiell gar nichts gegen die Aktie. Nur der Kurs macht ne pause  

150 Postings, 3852 Tage RainbowfuEnde

19.10.16 17:03

150 Postings, 3852 Tage RainbowfuKurz

02.11.16 17:21

998 Postings, 2996 Tage Max_V....läuft schön langsam an...

10.11.16 22:05
IntelliPharmaCeutics International Has Huge Upside With Limited Downside


998 Postings, 2996 Tage Max_V.Kommt diese Woche die News zum

14.11.16 10:48
PODRAS Patent? Ich denke schon...

Patent status: Application Is Considered Ready for Issue

Control Number: 14/790101

150 Postings, 3852 Tage RainbowfuGut

30.11.16 21:42
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) just announced the submission of its New Drug Application (NDA) for Rexista, it?s bioequivalent OxyContin product. The application comes a little later than first expected, but it?s now in the bag, and the result could be a game changer for the company. It?s targeting an abuse deterrent approval, and if the agency gives the asset a thumbs up for approval, and couples the approval with an abuse deterrent label, it could attract significant investor attention to IntelliPharmaCeutics. There?s also a strong potential catalyst on a commercialization partner announcement for the drug, meaning at its current valuation of $96 million (and taking into consideration a somewhat muted response to the latest NDA filing, there looks to be some degree of potential for a discount entry.

The FDA is now set to make a decision on Valeant Pharmaceuticals (NYSE:VRX)'s psoriasis drug, Brodalumab, on February 16, 2017. The Market Exclusive Intelligence Team set its sights on uncovering the truth about the delay. If you are invested in the stock, or are trading the event, you won't want to miss what we found.

200 Postings, 3269 Tage tollist hier

13.03.17 12:30
noch wer investiert?  

200 Postings, 3269 Tage tollhallo

14.03.17 13:56
No Hype - just the Facts.  Your complete source of news and realtime quotes from the TSX, TSX-V, CSE, Montreal, Nasdaq, NYSE, Amex and OTC Markets.
so ne interessante aktie und keine da?


998 Postings, 2996 Tage Max_V.Hallo toll

01.04.17 18:20
ja, ich bin auch schon eine Weile investiert und sehr überzeugt.  

998 Postings, 2996 Tage Max_V.Revenues verdoppelt bis Q3 2017 Cash flow positiv!

12.04.17 13:24

Intellipharmaceutics Announces First Quarter 2017 Results­maceutics-Announces-First-Quarter-2017-Results.html


200 Postings, 3269 Tage tollnews

12.05.17 16:46
No Hype - just the Facts.  Your complete source of news and realtime quotes from the TSX, TSX-V, CSE, Montreal, Nasdaq, NYSE, Amex and OTC Markets.  

200 Postings, 3269 Tage tollgute news

07.06.17 20:10

200 Postings, 3269 Tage tollhier

07.06.17 20:11
No Hype - just the Facts.  Your complete source of news and realtime quotes from the TSX, TSX-V, CSE, Montreal, Nasdaq, NYSE, Amex and OTC Markets.

4539 Postings, 3316 Tage centsucher...

27.07.17 17:21

Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista? (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain


Seite: Zurück 1 | 2 Weiter  
   Antwort einfügen - nach oben